NCT06066905Recruiting
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Source: ClinicalTrials.gov · Last updated 27 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 19 Sept 2023
- Start date
- 26 Oct 2023
- Primary completion date
- Dec 2026
- Lead sponsor
- Guangdong Provincial People's Hospital
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06066905
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 26 Oct 2023 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergic to the study drug;
- A gastrointestinal condition that prevents oral medication;
- active infection;
- other malignancies;
- HIV infection;
- HBV or HCV;
Lab values
- The QT interval is prolonged;
Other
- Dysfunction of vital organs;
- Pregnant or lactating women;
- Is participating in other clinical studies;
- The researchers did not consider it appropriate to participate in this study.
Who the study is looking for
- Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);
- ≥18 years old;
- ECOG≤3;
- lifespan≥3 months;
- Take contraceptive measures;
- Sign informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangdong Provincial People's Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
Related publications
- MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia.Ann Hematol · 2026 · PMID 42439986
This page is information, not medical advice. Discuss any trial with your doctor.